Cooperative Agreement U01CA290664
Award Date
7/8/24
Completion Date
6/30/29
Dollars Obligated
$947K
Federal Agency
National Cancer Institute
Federal Grant Program
93.393
Assistance Type
Cooperative Agreement
Place of Performance
Kansas City, KS 66160, USA
Similar Awards
The National Cancer Institute (NCI) awarded a $172,197 Project Grant (CFDA 93.395 - Cancer Treatment Research) to the University of Kansas Medical Center Research Institute, Inc. (KUMCRI) to establish and refine processes that facilitate clinical trials in cancer interception (active cancer prevention) at the University of Kansas Cancer Center (KUCC). The key products and services to be delivered under this 5-year grant include: 1) Hiring project navigators to facilitate study approvals for...
This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $159,574 to the University of Kansas Medical Center Research Institute, Inc. (KUMCRI) to increase access and participation to early phase clinical trials of experimental cancer therapies for underrepresented populations, including veterans. The key objectives are to develop sustainable strategies to extend access to the Experimental Therapeutics Clinical Trials Network (ETCTN)...
This Cooperative Agreement award from the National Cancer Institute (NCI), under the federal grant program "Cancer Cause and Prevention Research" (CFDA 93.393), aims to implement and evaluate a Comprehensive Survivorship Care (CSC) intervention across 14 Federally Qualified Health Center (FQHC) primary care clinics in South Florida. The $860,545 award will support a cluster randomized clinical trial to compare the effectiveness of the CSC intervention versus standard survivorship...
The National Cancer Institute (NCI) awarded a $1,729,890 Cooperative Agreement (CFDA 93.395 - Cancer Treatment Research) to The Washington University to develop and validate a new 3D imaging technology called SkinScan3D for improved monitoring of Kaposi sarcoma (KS) treatment response in East Africa. The project, titled "Precision Imaging to Evaluate Kaposi Sarcoma (PRIME-KS)", aims to refine the SkinScan3D device and usage protocols through human-centered design, compare its...
This $334,233 federal Project Grant awarded by the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research (CFDA 93.393) program supports a research project conducted by the University of South Carolina to examine disparities in cancer care and outcomes. The project aims to: Describe and compare patterns of novel targeted therapies for lung and colon cancer by race, socioeconomic status, and urban/rural designation, and their impact on survival disparities. Describe and...
This federal Project Grant award from the National Cancer Institute (NCI), under the Cancer Cause and Prevention Research program (CFDA 93.393), provides $327,496 to the University of Missouri System to design and develop implementation interventions aimed at improving the quality of active surveillance for men with favorable-risk prostate cancer. The objective is to assess key implementation determinants, design tailored interventions to support surveillance quality in urology practices, and...
The National Cancer Institute (NCI) awarded a $621,732 Project Grant under the Cancer Cause and Prevention Research (CFDA 93.393) program to The Medical University of South Carolina (MUSC) to evaluate a proactive identification and digital mental health intervention approach to address unmet psychosocial needs of individuals living with likely incurable cancer. The project aims to: 1) comprehensively assess the effectiveness of a proactive identification and digital mental health intervention...
This $2,282,687 federal Project Grant award from the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) supports a comprehensive research program to understand features of care integration in oncology that are associated with higher-quality care delivery and better outcomes for individuals with cancer. The grant funds a multi-institution research effort with four interrelated projects that will collect primary data through case studies and surveys, as well as...
This Project Grant award from the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) will fund a $1,338,648 hybrid effectiveness-implementation trial of the CARES intervention at the University of Pittsburgh's Hillman Cancer Center. CARES is an integrated EHR-based screening and stepped collaborative care intervention designed to improve health-related quality of life (HRQOL) for over 100,000 cancer patients evaluated and treated annually at the center. The study aims...
This $968,999 Project Grant award from the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research program (CFDA 93.393) supports a research study titled "OPTIMIZING SURVEILLANCE IN LUNG CANCER SURVIVORS WITH NOVEL IMAGING BIOMARKERS AND DEEP-LEARNING (OPTIMAL)". The study aims to optimize post-treatment surveillance for lung cancer survivors by incorporating risk-based strategies that leverage routinely available medical imaging data. The 5-year project, set...